Independent · non-commercial · publishes on a quarterly cycle|Current cycle 2026 Q3
Compound Evidence InstituteEvidence synthesis · established 2023Graded assessments of compounds, trials, methods and supply
Document set current to 30 July 2026
Public comment period · Evidence synthesis

Draft safety review: delayed gastric emptying and procedural sedation

Consultation on the draft safety review of delayed gastric emptying and residual gastric content in patients receiving an incretin receptor agonist who present for procedural sedation. The review assesses a signal drawn largely from imaging studies and case…

Document identifier
CEI-CP-018
Series
Public comment period
Version
1.0
Published
26 Dec 2025
Last reviewed
26 Dec 2025
Next review
26 Dec 2026
Identifier
10.71829/cei.cp.18
Certainty
Not rated
Cycle
2025 Q4
Window
12 Oct 2025 – 23 Nov 2025
Status
Closed
Submissions
15

§1Consultation and window

§1.1Window

Opened
12 October 2025
Closed
23 November 2025
Duration
42 days
Status
Closed — the disposition is published
Document under consultation
Synthesis: Delayed gastric emptying, residual gastric content and procedural…
Submissions received
15

§1.2Consultation questions

The secretariat put the following questions. A submission was not required to address them and several did not; the questions record what the Institute was uncertain about rather than restricting what a respondent could raise.

  1. Is the low certainty rating appropriate for a signal supported by observational imaging evidence and case reports rather than by randomised comparison?
  2. Should the review state a period of withholding, or state that the evidence does not support a specific period and record what professional bodies have advised?
  3. Is the absence of an event in trials of conventional size treated correctly, that is as uninformative rather than as reassurance?

§1.3How a submission is handled

  • Every submission is signed. The Institute publishes no anonymous submission.
  • Every submission carries a declared interest. A declaration of no interest is itself a declaration and is recorded as one. A declaration is not a disqualification and the Institute has never given a submission less weight on that ground.
  • A submission from an employee of a marketing-authorisation holder is identified as an industry submission on its face, following a unanimous consultation on the conflicts policy.
  • Every submission receives a secretariat response and a disposition. Submissions that are not accepted remain published in full; the Institute does not remove a submission because it disagrees with it.
  • There is no voting, no reputation score, no reply thread and no editing after receipt.

§1.4Outcome

The review was amended before ratification. It states no withholding period of its own, records the advice issued by professional bodies with attribution and date, and carries an explicit statement that the randomised evidence base was not designed to detect this outcome.

The disposition table, listing each submission with its disposition and the resulting amendment, is at §3.

Nothing published by the Institute is medical advice, a diagnosis, a prescription, a treatment recommendation or a purchasing recommendation. Compounds supplied for research use are not approved for human or veterinary use in any jurisdiction, and a favourable analytical assessment of a supplier is not a statement that any product is safe or effective. The Institute publishes certainty ratings and never recommendations. No telephone number, messaging handle or ordering channel appears anywhere on this site.